Heron Therapeutics, Inc. (HRTX)
0.3439
+0.01
(+4.21%)
USD |
NASDAQ |
Sep 04, 16:00
0.355
+0.01
(+3.23%)
After-Hours: 20:00
Heron Therapeutics Research and Development Expense (Quarterly) : 2.702M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.702M |
| March 31, 2026 | 2.385M |
| December 31, 2025 | 3.746M |
| September 30, 2025 | 3.17M |
| June 30, 2025 | 2.734M |
| March 31, 2025 | 2.279M |
| December 31, 2024 | 3.178M |
| September 30, 2024 | 4.465M |
| June 30, 2024 | 4.432M |
| March 31, 2024 | 4.608M |
| December 31, 2023 | 10.95M |
| September 30, 2023 | 13.56M |
| June 30, 2023 | 17.57M |
| March 31, 2023 | 13.82M |
| December 31, 2022 | 11.06M |
| September 30, 2022 | 25.54M |
| June 30, 2022 | 28.83M |
| March 31, 2022 | 42.07M |
| December 31, 2021 | 28.88M |
| September 30, 2021 | 28.60M |
| June 30, 2021 | 35.23M |
| March 31, 2021 | 38.12M |
| December 31, 2020 | 44.45M |
| September 30, 2020 | 49.18M |
| June 30, 2020 | 44.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.89M |
| December 31, 2019 | 48.28M |
| September 30, 2019 | 34.71M |
| June 30, 2019 | 41.42M |
| March 31, 2019 | 42.97M |
| December 31, 2018 | 39.89M |
| September 30, 2018 | 30.42M |
| June 30, 2018 | 30.16M |
| March 31, 2018 | 39.56M |
| December 31, 2017 | 47.86M |
| September 30, 2017 | 28.64M |
| June 30, 2017 | 28.00M |
| March 31, 2017 | 32.58M |
| December 31, 2016 | 29.50M |
| September 30, 2016 | 25.54M |
| June 30, 2016 | 27.29M |
| March 31, 2016 | 16.09M |
| December 31, 2015 | 16.26M |
| September 30, 2015 | 14.24M |
| June 30, 2015 | 16.18M |
| March 31, 2015 | 14.50M |
| December 31, 2014 | 14.20M |
| September 30, 2014 | 14.73M |
| June 30, 2014 | 14.43M |
| March 31, 2014 | 11.77M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp. | 19.42M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |